ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Thiamine pyrophosphate may protect indomethacin-induced small intestinal enteropathy in rats by inhibiting intestinal inflammation and oxidative stress.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Novel Protective Strategy Against Metformin-Induced Renal Injury Involving Adenosine Triphosphate and Thiamine Pyrophosphate.International journal of molecular sciences · 2026Article
- Comparative Proteomic Analysis ofJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-steroid anti-inflammatory drug (NSAID)-induced enteropathy is a clinically undesirable but highly prevalent problem. Thiamine pyrophosphate (TPP) has a role in reducing oxidative stress as well as acting as a coenzyme in enzymatic reactions. The aim of this study was to investigate the protective effect of TPP on the damage caused by indomethacin (IND), one of the NSAID group drugs, in the small intestine. In the experiment in which 32 rats were used, four groups were formed randomly (groups 1, 2, 3, 4; control, TPP, IND, IND + TPP group, respectively). Small intestinal injury was induced in group 3 and group 4 rats that were fasted 1 day beforehand by a single intragastric administration of 25 mg/kg IND. Half an hour before the model was created, 20 mg/kg TPP was administered to group 2 and group 4 by intragastric as pretreatment. Tissue changes, proinflammatory cytokines, oxidative stress status, macroscopic appearance, and histopathologic analysis were evaluated. All data were statistically analyzed, and significance was determined (p < 0.05). Prophylactic treatment with TPP resulted in maintenance of antioxidant enzymes (GPX, SOD) and GSH levels in small intestinal tissue analysis. However, the excessive increase in IND-induced lipid peroxidation (MDA) and total oxidant level (TOS) was not downregulated by TPP compared to group 3. Additionally, the treatment had no prophylactic effect on the reduction of proinflammatory cytokine (TNF-α, IL-6) levels in tissue. Histopathologic examination of the tissue revealed that IND disrupted the intestinal villus structure, causing erosive ulceration, degeneration, and inflammation. TPP reduced the inflamed areas and total tissue damage score in the IND group (p < 0.001). In this study, the positive effects of TPP use on some parameters in a short period of time suggested that TPP may produce more significant results with changes in the time and dose of use. Indeed, these beneficial effects obtained with a single dose suggest that TPP may provide protection in small intestinal enteropathy as an antioxidant and anti-inflammatory agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.